Competitors don't announce their next move. They file it, publish it, or quietly update a label, and the teams watching closely are the ones who see it coming. In a landscape this fast-moving, ad hoc competitive tracking isn't a minor gap, it's a strategic liability. Systematic, automated pharma competitive intelligence has become a necessity, not a nice-to-have, and Dr. Evidence is the platform built to make it possible: one source that monitors labels, submissions, approvals, and the scientific literature that surrounds them, so your team always knows where the market stands.
Regulatory affairs teams rely on Dr. Evidence for competitive labeling intelligence, tracking how competitor indications, safety language, and dosing evolve over time. Medical affairs teams use the same platform to maintain a current view of the broader scientific landscape their competitors are shaping. And corporate strategy and business development teams depend on it for pipeline monitoring, using competitive intelligence to inform partnership decisions, portfolio planning, and market positioning long before a deal is on the table.
Book a Demo
Manually tracking every competitor label change, submission, and approval across a portfolio is a full-time job that most teams don't have the bandwidth for, and the moment monitoring lapses is exactly when something important happens.
Dr. Evidence automates that work, tracking competitor label changes, new submissions, and approvals across markets and delivering alerts when something shifts. Instead of discovering a competitive move weeks after the fact, your team knows as soon as it happens.
Real competitive intelligence in the pharmaceutical industry goes deeper than headlines. Dr. Evidence gives your team label-level depth: how competitor indications are worded, how safety language and adverse event profiles compare, and how dosing regimens differ across products and geographies. That level of detail directly informs regulatory positioning and label strategy because knowing what a competitor's label actually says, not just that it exists, is what turns intelligence into an advantage at the negotiating table.
Labels are only part of the picture. Dr. Evidence draws from a broad set of sources beyond approved labeling (regulatory approval packages, clinical trial data, scientific congresses, and published literature), giving your team a comprehensive view of the competitive landscape that label-only tools can't match. This is the differentiator that separates true drug intelligence from a label database: the ability to see how a competitor's clinical evidence, regulatory filings, and public communications fit together, so your team can educate, influence, and collaborate with peers from a position of genuine landscape awareness.
Competitive threats don't respect borders, and neither does Dr. Evidence's platform. For global teams managing competitive strategy across multiple markets simultaneously, the ability to monitor labels, submissions, and literature across major geographies from one system, rather than stitching together region-specific tools, is a meaningful advantage. It's life sciences competitive intelligence built for how global portfolios operate, not for a single market in isolation.
Data alone doesn't win a competitive position; what you do with it does. Dr. Evidence is built to move your team from raw competitive intelligence to concrete regulatory strategy, label negotiation preparation, and commercial planning. When your team can see a competitor's full label and regulatory history alongside the clinical and scientific literature behind it, decisions about positioning, timing, and negotiation stop being reactive and start being deliberate. That's the outcome biopharma competitive intelligence should have always delivered: not just visibility, but a genuine head start.
The teams with the clearest competitive picture are rarely the ones searching hardest — they're the ones with the right platform doing the searching for them.
Book a Demo to see Dr. Evidence's pharma labeling software in action to see exactly how it works.